Phio Pharmaceuticals Corp.
corporate_fare Company Profile
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 14 items for PHIO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 8/10. Across its 14 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for PHIO spans 8-K, 10-Q, 424B5, 10-K.
Recent high-impact activity:
- Phio Receives Nasdaq Bid-Price Deficiency Notice, Has 180 Days to Regain $1.00 Compliance
- Phio 10-Q: Going-Concern Warning, $10.6M Cash, Nasdaq Bid-Price Deficiency
- Phio Pharmaceuticals Begins Commercial-Scale Production of Lead Drug PH-762
- Phio Pharmaceuticals Reports Widened Q1 Loss Amid Increased R&D for PH-762, Maintains 12-Month Cash Runway
- Phio Pharmaceuticals Completes PH-762 Phase 1b Trial with Favorable Data, Targets Q2 FDA Submission
Financial Snapshot
Short Interest & Short Volume
1.49 days to coverFINRA reported short interest of 86,344 shares in PHIO as of the October 30, 2026 settlement, a 36.7% decrease from the prior period — about 1.5 days to cover at its recent average daily volume. On November 20, 2026, 15.2% of PHIO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.